Aurobindo Pharma's net profit fell 10% to Rs 846 crore in Q3 FY25, while revenue rose to Rs 7,979 crore. The company attributes this to volume growth and new launches.
HYDERABAD: Degrowth in its US formulations business dragged down Aurobindo Pharma’s consolidated net profits for the third quarter ended December 31, .